Royalty Pharma plc (NASDAQ:RPRX) price on current trading day, fall -0.04% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $33.37.
A look at the stock’s price movement, the level at last check in today’s session was $33.38. The PE ratio in trailing twelve months stood at 17.40. Turning to its 52-week performance, $34.20 and $24.05 were the 52-week high and 52-week low respectively. Overall, RPRX moved 4.46% over the past month.
Royalty Pharma plc’s market cap currently stands at around $19.24 billion, with investors looking forward to this quarter’s earnings report slated for in March. The company has a Forward Dividend ratio of 0.85, with its dividend yield at 2.55%. As such, investors might be keen on an upside in the stock’s price ahead of the scheduled earnings report.
Analysts have a consensus estimate of 724.69M for the company’s revenue for the quarter, with a low and high estimate of 643.37M and 806M respectively. The average forecast suggests up to a 27.59% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 2.95B, representing a 30.11% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RPRX is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 5 recommend RPRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
The technical evaluation for the stock shows the PEG ratio is 1.36, with RPRX’s current price about 3.00% and 12.87% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 71.62, while 7-day volatility ratio is 2.58% and 2.10% in the 30-day chart. Further, Royalty Pharma plc (RPRX) has a beta value of 0.47, and an average true range (ATR) of 0.71. Analysts have given the company’s stock an average 52-week price target of $51, forecast between a low of $51 and high of $51. Looking at the price targets, the low is -52.83% off recent price level in today’s trading while to achieve the yearly target high, it has to move -52.83%. Nonetheless, investors will most likely welcome a -52.83% jump to $51 which is the analysts’ median price.
If we refocus on Royalty Pharma plc (NASDAQ:RPRX), historical trading data shows that trading volumes averaged 3.98 million over the past 3 months. The company’s latest data on shares outstanding shows there are 445.99 million shares.
The 14.19% of Royalty Pharma plc’s shares are in the hands of company insiders while institutional holders own 74.42% of the company’s shares. Current price change has pushed the stock 30.79% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RPRX stock continues to rise going into the next quarter.
